role enhanced vagal activity ischemic ventricular tachycardia pharmacologic basis inefficiency effects pharmacologic modulation vagal activity ischemic ventricular tachycardia conscious dogs permanent anterior coronary artery LAD occlusion Studies spontaneous ventricular tachycardia cycle msec hours LAD occlusion inducible monomorphic ventricular tachycardia cycle msec days LAD occlusion Edrophonium cholinesterase inhibitor methacholine mg muscarinic agonist significant effect rate QRS morphology type tachycardia severe slowing sinoatrial rate atropine micrograms/kg effect rate QRS morphology type tachycardia attempt myocardial drug delivery ischemic infarcted left ventricle edrophonium mg/kg methacholine mg great cardiac vein significant therapeutic advantage systemic intravenous route Sympathetic beta blockade therapeutic outcome edrophonium methacholine direct indirect enhancement cardiac vagal activity effect ischemic ventricular tachycardia model subacute myocardial infarction lack efficacy independent myocardial drug delivery ventricular site sympathetic activity lack efficacy ischemia-mediated degeneration vagal nerve terminals altered responsiveness muscarinic receptors infarcted arrhythmogenic myocardial sites 